Home What’s New

16

Sep2024

*NEW* Report Release: “Issues and Opportunities to Modernize Private Drug Plan Sustainability in an Evolving Market”

PDCI Market Access, a Division of McKesson Canada Corporation has released a whitepaper investigating the design and sustainability of private drug benefits in Canada. The report, commissioned by Innovative Medicines Canada, uncovers critical gaps in private insurance risk pooling that leave many small plan sponsors with tough decisions ... Read More

21

Aug2024

Connect with PDCI Market Access at CDA Symposium 2024

PDCI Market Access, a division of McKesson Canada, is a Platinum Sponsor of CDA's Symposium 2024 taking place in Ottawa on September 4-6, 2024. PDCI’s Kaitlyn Proulx, Andrea Lau, Ara Salazar, Tuhin Maity, Sam Ali and Hussein El-Khechen, along with our McKesson colleagues ... Read More

28

Jun2024

PMPRB Releases Long Awaited Discussion Guide as Phase 2 of the New Guidelines Consultation Process

On Wednesday, June 26th, PMPRB initiated Phase 2 of the consultation process by publishing the Discussion Guide that will help shape future guidelines. They have indicated that changes to the Guidelines are necessary to address their new legislative and jurisprudential reality and are committed to modernizing and simplifying ... Read More

31

Jan2024

CADTH Update Introduces Streamlined Economic Reports and Launches BIA Template Consultation

On Friday, CADTH’s Pharmaceutical Reviews Update – Issue 43 introduced a number of updates pertaining to its Reimbursement Reviews procedures. These include: Budget Impact Analysis (BIA) Consultation: CADTH is seeking stakeholder feedback on its draft BIA template tool. The tool is an optional resource to ... Read More

20

Dec2023

New Issue of INSIGHTS Released

PDCI released a new issue of PDCI Market Access INSIGHTS, featuring research and opinion on the evolving state of private health insurance in Canada. In this Issue:... Read More

19

Dec2023

Happy Holidays from PDCI!

As another memorable year draws to a close, the team at PDCI Market Access would like to express its sincere gratitude and appreciation for all our clients, partners, and people who support us in our purpose to improve health outcomes for all.We hope your holiday season is filled ... Read More

02

Oct2023

PMPRB Publishes Final Decision on Amended Interim Guidance

On September 27, 2023, the Patented Medicine Prices Review Board (PMPRB) published its final decision regarding the Amended Interim Guidance first proposed on June 20, 2023.Effective immediately, the proposed amendments to the Interim Guidance are implemented without changes, notwithstanding the concerns raised by many of the ... Read More

03

Aug2023

PCPA Seeks Stakeholder Input On Its Proposed Process To Implement CADTH Time-Limited Recommendations

The pan-Canadian Pharmaceutical Alliance (pCPA) introduced its proposed pCPA Temporary Access Process (pTAP) and invited stakeholders’ input on the process, its principles and conditions by August 18th, 2023.   The proposed pTAP and its associated principles are intended to inform pCPA negotiations and product listing agreements for ... Read More

11

Jul2023

CADTH Announces Changes to Reimbursement Reviews Process & Fee Schedule Update

On June 5, 2023, the Canadian Agency for Drugs and Technologies in Health (CADTH) announced a series of process improvements it plans to explore or add to its drug reimbursement review process. These changes - aimed at gaining efficiencies, reducing timelines and improving transparency – include:... Read More

22

Nov2022

CADTH Pharmaceutical Reviews Update Includes Launch of RWE Guidance Consultation

On November 10, 2022, among other procedural updates included in the CADTH Pharmaceutical Reviews Update Issue 32, CADTH published its Real-World Evidence (RWE) Steering Committee’s anticipated Proposed RWE Reporting Guidance and initiated a public consultation on the guidance open now through January 6, 2023.What to know: The ... Read More